A Phase 2, Open-label, Multicenter Study of TL-895 in Subjects with Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis and Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis
To determine the RP2D and schedule of TL-895 in each cohort. The SRC will determine the RP2D and schedule for Cohorts 1, 2 and 3 based on safety and tolerability data obtained from each arm of that cohort.
University of Colorado Hospital
Brandon Mcmahon, MD
Protocol Number: 20-3032
More information available at ClinicalTrials.gov: NCT04655118
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers